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with PN in cT1a and laparoscopic RN in cT1b were evalu-
ated with logistic regression analyses.
Results An increase in nephron-sparing treatment strate-
gies (NSS) of cT1a patients (Ntotal = 2436) was observed; 
in 2014, 67 % underwent NSS (62 % PN and 5 % thermal 
ablation). Age, a non-central tumor localization and being 
treated in a high-volume hospital were associated with PN. 
Although NSS were applied more frequently over time, the 
majority (70 %) of cT1b patients (Ntotal = 2205) underwent 
RN in 2014, mainly performed laparoscopically. Increasing 
tumor size, tumor localization in the right kidney and being 
treated in a university hospital were associated with a lower 
probability of a laparoscopic RN versus open. Treatment in 
a high-volume hospital was associated with a higher prob-
ability of laparoscopic RN.
Conclusions Dutch patients with cT1 renal cancer are pre-
dominantly treated according to current guidelines. Data of 
this pre-specified quality indicator analysis of a urological 
national guideline may serve as a model for international 
comparison of treatment of cT1 renal cancers.
Keywords Population-based · Cancer registry · Guideline 
adherence · Kidney cancer · Partial nephrectomy
Introduction
Partial nephrectomy (PN) is recommended as treatment of 
choice for small renal cancers. The paradigm shift from radi-
cal nephrectomy (RN) to PN is based on a prospective ran-
domized trial [1] which demonstrated similar oncological 
outcomes for both. In addition, several retrospective observa-
tional studies revealed comparable outcomes [2–5]. PN pre-
serves renal function [2, 3, 6] and by this minimizes cardio-
vascular comorbidity [7, 8] and chronic kidney disease [2, 4].
Abstract 
Purpose For decades, small renal cancers are treated by 
radical nephrectomy (RN). Current guidelines recommend 
partial nephrectomy (PN) to preserve renal function and 
minimize cardiovascular comorbidity. As adherence to 
guidelines is largely unknown and international comparison 
to evaluate quality of health care is lacking, an pre-spec-
ified guideline evaluation of quality indicators concerning 
management of cT1 renal cancers was performed.
Methods We performed a cohort study including patients 
with cT1 renal cancer between 2010 and 2014, identified 
through the Netherlands Cancer Registry. Time trends and 
variation in treatment were described. Factors associated 
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The guidelines of the American Urological Association 
(AUA) from 2009 [9] and European Association of Urol-
ogy (EAU) from 2014 [10] (http://www.uroweb.org) rec-
ommend PN for small kidney tumors (cT1a/cT1b, ≤7 cm) 
whenever possible. The Dutch guideline from 2010 (www.
oncoline.nl) recommends PN for cT1a (≤4 cm) and states 
that for cT1b (>4 to ≤7 cm) RN is no longer the standard. 
All guidelines further mention that other nephron-sparing 
strategies (NSS) like thermal ablation (i.e., cryosurgery or 
radiofrequency ablation) are alternatives if PN is no option, 
due to technical reasons (e.g., anatomically complex 
masses) or high risk of surgical complications (e.g., in case 
of severe comorbid conditions). Finally, active surveillance 
may be considered, particularly in patients with cT1 tumors 
with a short life expectancy or severe comorbidities. Pro-
spective cohort studies have shown acceptable outcomes in 
this patient group although the growth rate remains unpre-
dictable [11].
Population-based studies from the USA including 
patient data until 2008 observed that, despite an increase in 
PN, RN remained the preferred procedure in almost 70 % 
of all kidney cancer patients [12, 13]. It was argued that the 
introduction of laparoscopic RN may have been favored as 
minimally invasive approach over the more complex PN 
which, before the advent of robot-assisted surgery, was fre-
quently performed as open procedure. Generally, adherence 
to renal cancer guidelines is unknown which afflicts inter-
national comparison of healthcare quality.
Aim of this study was to evaluate adherence to recom-
mendations in the Dutch guideline and to evaluate cur-
rent management and variation in clinical practice. Based 
on a set of pre-specified quality indicators which included 
management of small renal cancers, we performed a popu-
lation-based study using the Netherlands Cancer Registry 
(NCR).
Patients and methods
The 2010 update of the Dutch Renal Cell Carcinoma guide-
line included an agreement to test its adherence based on 
pre-specified quality parameters. One of the parameters 
was management of cT1 renal cancers. Patients diagnosed 
with a clinical T1 renal cancer (International Classifica-
tion of Diseases-Oncology (ICD-O), 3rd Edition code: 
C64) were selected from the NCR held by the Netherlands 
Comprehensive Cancer Organization (IKNL). Since 1989, 
all cancer diagnoses are recorded in the NCR and its com-
pleteness is estimated at approximately 95 % [14]. Patients 
diagnosed between 2010 and 2014 and age at diagnosis of 
≥18 years were included. Patients without pathological 
confirmation of a renal cancer subtype [15] were excluded. 
Patient, tumor and treatment characteristic were retrieved 
from the NCR. All data available in the NCR are collected 
by review of medical files by well-trained registration 
staff in a uniform and standardized way. In case data were 
incomplete, an additional effort was made to complete the 
data by consulting the primary medical files again.
Treatment was categorized into four groups: PN, RN, 
thermal ablation and no treatment/active surveillance/other 
treatments. No distinction could be made for active surveil-
lance versus no treatment; both were classified as ‘no treat-
ment.’ Hospitals were grouped according to type: university 
hospitals, ‘top clinical’ hospitals and community hospitals). 
University hospitals, including the Netherlands Cancer 
Institute, represent nine large to midsize hospitals which 
offer specialized care and are responsible for the training 
of medical specialists. The ‘top clinical’ hospitals include 
large- to midsize hospitals which provide, next to standard 
care, specialized care in specific areas, are not affiliated 
with a university but involved in the training of medical spe-
cialists. The community hospitals include all other, mostly 
smaller-size, hospitals and provide standard care. Patients 
treated in foreign hospitals were excluded from all hospi-
tal specific analyses. Hospitals were also grouped according 
to oncological nephrectomy volume for renal cancer (<10, 
10–19 and ≥20 procedures/year) as the national guideline 
recommends a minimum of 10 nephrectomy procedures.
With descriptive analyses, we provide insight into treat-
ment trends over time between 2010 and 2014 for cT1a and 
cT1b renal cancer, stratified by age (<70 vs. ≥70 years at 
diagnosis. Five-year relative survival rates and 95 % confi-
dence intervals (95 % CIs) are calculated for different treat-
ment modalities. Follow-up was completed until January 1, 
2015. We also compared differences in treatment between 
different types of hospitals for recently diagnosed patients 
(2012–2014). Uni- and multivariable logistic regression 
analyses were performed to identify factors associated with 
PN versus RN for patients diagnosed with cT1a cancer and 
factors associated with laparoscopic versus open RN for 
patients diagnosed with cT1b cancer in 2012–2014.
Comparative analyses of hospital stay (time in days 
between nephrectomy and discharge) and postoperative 
mortality (mortality within 30 days after surgery), after PN 
versus RN by tumor stage, were performed using a Wil-
coxon-rank test and Chi-square test, respectively.
All analyses were performed with SAS 9, SAS institute 
Inc 2011, Cary, NC, USA. The study was approved by the 
internal review board of IKNL.
Results
Overall 2436 patients with a cT1a renal cancer were diag-
nosed between 2010 and 2014. Subtypes were 68 % clear 
cell, 15 % papillary, 6 % chromophobe, 0.3 % sarcomatoid, 
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9 % unspecified and 1 % other. Figure 1a–c shows the pro-
portion of cT1a patients by different treatment modalities. 
Over time, a clear increase in PN was observed. In 2014, 
62 % underwent PN, 29 % RN, 5 % had thermal ablation, 
and only 4 % were not treated or followed an active surveil-
lance protocol. Large differences were observed between 
Fig. 1  a Distribution of 
treatment modalities in cT1a 
renal cancer patients over 
time (2010–2014). b distribu-
tion of treatment modalities 
in cT1a renal cancer patients 
younger than 70 years over time 
(2010–2014). c distribution of 
treatment modalities in cT1a 
renal cancer patients of 70 years 
or older over time (2010–2014)
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patients ≥70 and <70 years. Thermal ablation as alternative 
NSS is predominantly used in older patients, and no clear 
increase since 2010 was observed. The overall 5-year rela-
tive survival rate of patients with cT1a was 93 % (95 % CI 
89.6–95.8 %). Patients with PN or thermal ablation had a 
similar 5-year survival of 95.3 % (95 % CI 90.7–98.7 %) 
and 95.3 % (95 % CI 84.1–102.3 %), respectively. Patients 
with RN had a slightly worse survival of 92.9 % (95 % CI 
87.1–97.3 %). Due to small numbers, the 5-year survival of 
patients with no active treatment could not be calculated.
In total, 2205 patients with a cT1b renal cancer were 
diagnosed. Histological subtypes were 73 % clear cell, 
11 % papillary, 5 % chromophobe, 0.5 % sarcomatoid, 
8.5 % unspecified and 1 % other. NSS were applied more 
frequently over time for cT1b renal cancer (Fig. 2a–c), but 
RN remained the preferred treatment. In 2014, 70 % of 
all T1b patients underwent a RN and this proportion was 
largely independent of age. The overall 5-year relative sur-
vival rate of patients with cT1b was 87.3 % (95 % CI 83.3–
90.8 %). Patients with PN had a 5-year survival of 93.1 % 
(95 % CI 80.4–100.5 %). Patients with RN had a slightly 
worse survival of 88.8 % (95 % CI 84.6–92.3 %). Due to 
small numbers, the 5-year survival of patients with thermal 
ablation or no active treatment could not be calculated.
In Fig. 3a, treatment of cT1a renal cancer stratified by 
hospital type of diagnosis is presented. The majority of 
patients diagnosed in a university hospital underwent NSS; 
53 % PN mostly performed laparoscopically and almost 
25 % thermal ablation. Approximately 20 % of all patients 
had a RN.
Patients diagnosed in the top clinical hospitals and com-
munity hospitals were treated slightly different. The major-
ity underwent a PN (57 and 61 %, for top clinical and com-
munity hospitals, respectively) and a small proportion of 
patients had thermal ablation (6.5 and 2.5 %, respectively). 
A fair part of the patients (>30 %) were still treated with 
RN.
Patients with a cT1b tumor diagnosed in a university 
hospital had more often NSS (almost 40 % vs. approxi-
mately 20 % for patients diagnosed in top clinical and com-
munity hospitals, Fig. 3b). In over 50 % of all patients with 
a PN, the procedure was done laparoscopically. No large 
differences were seen between different hospital types. 
Only 13–17 % of these patients were treated with an open 
RN.
Multivariable analyses of patients with cT1a (supple-
mentary Table 1) revealed that lower age is associated with 
a higher probability of PN as well as being treated in a 
high-volume hospital. In addition, PN was more often per-
formed for tumors in the upper or lower pole of the kidney.
For patients with cT1b, increasing tumor size, tumor 
localization in the right kidney and being treated in a uni-
versity hospital were factors significantly associated with 
a lower probability of a laparoscopic versus open RN in 
the multivariable analyses. Being treated in a high-volume 
hospital was associated with a higher probability of laparo-
scopic surgery (supplementary Table 2).
Duration of hospital stay and postoperative mortality
Postoperative mortality after cT1a tumor surgery was 
0.2 % (N = 2, both RN; p value χ2 0.05) and 0.3 % for 
cT1b patients (N = 4, all RN). Due to small numbers, the 
association between type and volume of hospital and post-
operative mortality could not be studied. Median hospital 
stay for cT1a patients was 4 days with PN and 4 days with 
RN for cT1b patients 5 days with PN and 4 days with RN.
Discussion
A clear trend over time from RN toward PN was observed 
in patients with cT1a renal cancer; in 2014, the major-
ity was treated according to guideline recommendations 
with NSS, predominantly PN. The majority of both PN 
and RN were performed laparoscopically. Limited vari-
ation in treatment modalities was observed for patients 
diagnosed in different hospital types. Most prominent dif-
ferences were that patients diagnosed with cT1a cancer in 
a university hospital were more often treated with thermal 
ablation and less often with RN compared to patients diag-
nosed in top clinical or community hospitals. Younger age, 
non-central tumors and being treated in a high-volume hos-
pital were significantly associated with higher probability 
of PN versus RN for cT1a cancers. Referral from low- to 
high-volume hospitals for a PN probably partly explains 
the observed difference between low- and high-volume 
hospitals.
Concerning cT1b, PN was more frequently performed in 
recent years, although RN remained the preferred treatment 
in 2014, with the majority performed laparoscopically. 
Large difference in proportion of patients treated with NSS 
was observed for patients diagnosed in a university hospital 
versus other hospitals; approximately 40 versus 20 % of the 
patients underwent NSS, respectively. Treated in a high-
volume hospital appeared to be strongly associated with a 
laparoscopical intervention. Again referral to high-volume 
hospitals specifically for a laparoscopic treatment may be 
partly responsible.
Our findings largely resemble Swedish data, which is the 
only recent population-based study on RCC [16]. In Sweden, 
a significant change over time toward NSS for both cT1a and 
cT1b renal cell cancers was observed, although the absolute 
proportion of patients with NSS was lower (62 % of treated 
cT1a patients with NSS vs. 67 % of all cT1a patients found 
in our study). Young age was associated with PN as well. 
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They reported strong variation between university hospitals 
(62 % NSS for cT1a) and intermediate-volume hospitals 
with an annual average of 10–30 kidney surgeries (34 %) 
and low-volume hospitals with <10 kidney surgeries (11 %). 
This is in line with our findings that university hospitals and 
high-volume hospitals more often perform NSS.
Fig. 2  a Distribution of 
treatment modalities in cT1b 
renal cancer patients over 
time (2010–2014). b Distribu-
tion of treatment modalities 
in cT1b renal cancer patients 
younger than 70 years over time 
(2010–2014). c Distribution of 
treatment modalities in cT1b 
renal cancer patients of 70 years 
or older over time (2010–2014)
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Studies from the USA based on the National Inpatient 
Sample evaluating trends over time concerning NSS or PN 
revealed a clear increase over time, although the general 
conclusion was that PN remained underused [12, 13, 17]. 
PN increased from 15 % in 2002 to 25 % in 2008 [13], but 
in 2008 RN was still applied in 67 % of all patients with 
cT1 renal cancers [12]. In both studies [12, 13], treatment 
could not be evaluated by tumor stage, precluding a direct 
comparison with our study. Another US study based on the 
SEER database, including only patients with renal tumors 
≤4 cm, reported a proportion of 45 % for PN in 2006 [18]. 
However, though the studies were recently published, the 
cutoff data for analysis were 7–9 years ago. It is conceiv-
able that in recent years the trend toward PN improved in 
the USA. Female patients, elderly and those living in rural 
locations were inversely associated with PN. Similar to our 
study, in all US studies younger age was significantly asso-
ciated with PN. Other factors that might be associated with 
PN included urban hospital location, surgery at teaching 
hospitals and large hospital capacity [12, 13, 17]. Factors 
inversely associated with PN were chronic kidney disease 
and comorbidities (diabetes, hypertension) [12].
As mentioned, it is recommended by the European 
and US guidelines to treat patients with renal cancers of 
4–7 cm (cT1b) with a PN as well, although data from a 
randomized controlled trial are only available for tumors 
up to 5 cm. However, the aim to preserve renal function as 
much as possible has triggered PN in larger tumors despite 
an increased surgical challenge and tumor size-related risk 
of progression and survival. From two recent reviews, it 
can be concluded that survival rates appear to be similar 
and renal function is better preserved for patients with 
cT1b renal cancers with PN versus RN [19, 20]. How-
ever, current evidence is based on small case series and 
retrospective observational studies and confounding by 
indication might have played a role. Despite the advan-
tages of PN in cT1b cancers, the current real-world treat-
ment is (laparoscopic) RN. A likely explanation for this 
Fig. 3  a Proportion of cT1a 
renal cancer patients by treat-
ment modality in the period 
2012–2014 by type of hospital 
of diagnosis. b Proportion of 
cT1b renal cancer patients by 
treatment modality in the period 
2012–2014 by type of hospital 
of diagnosis
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observation is that given the complexity and technical 
reconstructive skills required for either open, laparoscopic 
or robot-assisted PN, laparoscopic RN may be easier to 
learn and offered as the preferred minimally invasive 
approach.
Our data show that being treated in a university hospital 
was associated with a lower probability of a laparoscopi-
cally RN compared to top clinical and community hos-
pitals. This may be explained by the fact that the overall 
proportion of cT1b patients treated with RN in university 
hospitals is significantly lower, because a substantial part is 
being treated with NSS. Potentially, cT1b cancers not eligi-
ble for NSS were the more complex cases resulting in open 
RN being the preferred treatment.
One limitation of our study was the inclusion of small 
renal cancers only, whereas a part of the small renal masses 
is benign. Therefore, all results only reflect the manage-
ment of small renal cancers. In addition, the slightly better 
5-year survival for patients who underwent PN compared 
to those with RN should not be over-interpreted. Factors 
such as younger age in patients with PN may have affected 
the results which demonstrate considerable overlap for the 
95 % confidence intervals of the 5-year survival after PN 
and RN.
 In conclusion, NSS is increasingly applied in the 
Netherlands. The vast majority of patients are treated 
according to current guidelines. Compared to a recent 
analysis from another European country, the Netherlands 
seems to apply NSS slightly more frequently. Assess-
ment of the adherence to national and European guide-
lines is of importance to evaluate the quality of health 
care across member states of the European Union and 
beyond. Therefore, pre-specified quality indicators and 
internationally uniform instruments for data collection 
are needed.
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